D. Boral Capital remains Buy on Plus Therapeutics Inc. (PSTV) following CNSide data

D. Boral Capital analyst Jason Kolbert reiterated a Buy rating and $3.00 price target on Plus Therapeutics Inc. (NASDAQ: PSTV)

The analyst commented, "Plus Therapeutics highlighted new health economics work showing CNSide may reduce leptomeningeal metastases-related healthcare costs by about 40%, which we view as a commercially relevant datapoint as the company pushes the assay into broader U.S. launch. The key takeaway is not that this changes the clinical profile of the platform, but that it strengthens the reimbursement and adoption narrative by framing earlier LM detection and treatment optimization in economic terms that matter to payers and health systems. In our view, that is particularly important for a company whose near-term value creation depends not only on clinical differentiation, but also on proving that CNSide can fit into real-world care pathways and budget frameworks."

For an analyst ratings summary and ratings history on Plus Therapeutics Inc. click here. For more ratings news on Plus Therapeutics Inc. click here.

Shares of Plus Therapeutics Inc. closed at $0.24 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results